ClinicalTrials.gg
CompletedNCT06424470Updated Jun 2, 2026

Study on the Treatment of Prurigo Nodularis With Stapokibart Injection

A Phase 3 interventional study of Stapokibart and Placebo in Prurigo Nodularis, sponsored by Keymed Biosciences Co.Ltd. Completed at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-06-02.

Sponsored by Keymed Biosciences Co.Ltd · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
200
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

This study is a multicenter, randomized, double-blind, placebo-controlled phase III clinical study to evaluate the efficacy and safety of Stapokibart Injection in the treatment of subjects with prurigo nodularis, and observe pharmacokinetic characteristics, pharmacological effects, and immunogenicity.

Read the detailed description

Chronic prurigo (CPG) is an independent chronic inflammatory skin disease characterized by chronic itching and multiple local or systemic prurigo lesions. Prurigo nodularis (PN) is the main subtype of CPG.

02

Conditions studied

  • Prurigo Nodularis

Browse trials for

03

In context

Prurigo

38 studies on the registry are indexed under Prurigo; 10 are open to participants now.

This study's enrollment of 200 is above the median of 135 across 31 interventional studies indexed under Prurigo.

Browse Prurigo studies →

Lead sponsor

Keymed Biosciences Co.Ltd is the lead sponsor of 68 studies on the registry; 34 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Able to understand and agree to comply with the experimental process of this study and voluntarily sign the form.
  • 18 ≤ Age ≤ 75 years old.
  • Received at least 2 weeks of moderate or more potent topical therapy with insufficient efficacy.

Exclusion criteria

Exclusion Criteria:

  • With drug-induced prurigo nodularis.
  • With diseases.
  • With severe liver and kidney function damage at the screening.
  • With malignant tumors within the first 5 years before the screening.
  • Plan to undergo major surgical procedures during this study.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
200 participants (actual)

Study arms

  • Experimental
    Stapokibart

    Stapokibart Injection, subcutaneous injection (SC)

    Biological: Stapokibart

  • Placebo comparator
    Placebo

    subcutaneous injection (SC)

    Other: Placebo

Interventions

  • BiologicalStapokibart

    Stapokibart Injection

  • OtherPlacebo

    Placebo

06

What researchers measure

Primary outcomes

  1. Proportion of subjects with ≥4-point improvement from baseline in the Worst Itch Numerical Rating Scale (WI-NRS) at week 24

    The Worst Itch Numerical Rating Scale (WI-NR) is a patient-reported outcome (PRO) consisting of individual items with scores ranging from 0 ("no itching") to 10 ("the most severe itching imaginable"). Subjects are required to use this scale to rate the severity of their most severe itching in the past 24 hours.

    Time frame: Up to week 24

Secondary outcomes

  1. Proportion of subjects with Investigator's Global Assessment score of 0 or 1 for PN stage (IGA-CNPG S) at week 24

    IGA-CNPG-S stands for Investigator Global Assessment of Chronic Nodular Prurigo - Severity scale, a clinical tool used to rate the overall severity of chronic nodular prurigo (CNPG) by evaluating lesion number, size, and inflammation.

    Time frame: Up to week 24

  2. Change from the baseline in the WI-NRS at each other visit

    Time frame: Up to week 24

  3. Proportion of subjects with Investigator's Global Assessment score of 0 or 1 for PN Activity (IGA-CNPG A) at each visit

    A clinician-assessed scale to evaluate the overall appearance of lesions in chronic nodular prurigo

    Time frame: Up to week 24

  4. Change from baseline in Dermatology Life Quality Index (DLQI) score at each visit

    A patient-reported questionnaire measuring the impact of skin disorders on daily life and quality of life.

    Time frame: Up to week 24

  5. Change from baseline in Skin Pain NRS at each visit

    A numerical rating scale for patients to self-assess the intensity of skin pain.

    Time frame: Up to week 24

  6. Change from baseline in Sleep NRS at each visit

    A numeric scale used to quantify sleep disturbance caused by disease symptoms.

    Time frame: Up to week 24

  7. Change from baseline in Hospital Anxiety and Depression Scale (HADS) at each visit

    A validated scale for screening anxiety and depression symptoms in clinical populations.

    Time frame: Up to week 24

  8. Change from baseline in the European Health Questionnaire 5 Dimensions (EQ-5D-5L) at each visit

    A standard five-dimension tool to evaluate general health status and health-related quality of life.

    Time frame: Up to week 24

  9. Safety parameters

    Incidence of treatment-emergent adverse events (TEAEs).

    Time frame: Up to week 32

  10. Pharmacokinetics (PK)

    Concentration of CM310 in serum

    Time frame: Up to week 32

  11. Pharmacodynamics (PD)

    Change from baseline in serum thymus activation-regulated chemokine (TARC) concentration.

    Time frame: Up to week 32

  12. Anti-drug antibodies (ADA)

    Incidence of ADA.

    Time frame: Up to week 32

  13. Pharmacodynamics (PD)

    Change from baseline in serum total immunoglobulin E (IgE) concentration.

    Time frame: Up to week 32

07

Study locations

1 site
  • The First Hospital of China Medical University
    Shenyang, Liaoning, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2024 to primary completion in Feb 2026, 19 months.

How these figures are worked out, and which studies are left out of them.

Registered
May 16, 2024
First posted
May 22, 2024
StartActual
Jun 25, 2024
Primary completionActual
Feb 11, 2026
CompletionActual
Feb 11, 2026
Last update
Jun 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06424470
Responsible party
Sponsor
First posted
May 22, 2024
Start date
Jun 25, 2024
Primary completion
Feb 11, 2026
Completion
Feb 11, 2026
Last update
Jun 2, 2026

Study contacts

Xinghua Gao
principal investigator · First Hospital of China Medical University

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Stapokibart

Start the discussion